Gene-Disorder Association · Article
Gene
MET MET Proto-Oncogene, Receptor Tyrosine Kinase
×
First reported
1993
Supporting publications
17
Manually curated Approved treatment annotated
Association Review
In brief The association between MET (MET Proto-Oncogene, Receptor Tyrosine Kinase) and Lung Non-Small Cell Carcinoma is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
0
Compounds
13
Trials
1,252 of 4,047 via MET compounds
Publications
17
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access 02
Provenance
Evidence and sources 1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access 3 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access 04
Lung Non-Small Cell Carcinoma
The disorder 6 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access 05
Mechanism overlap
Shared mechanisms 1 shared pathway
Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access 06
Interventions
Therapeutics 13 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access 07
Human studies
Clinical trials 4,047 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access 17 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access 09
Provenance
References & sources 22 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access 
